/
Other
Allogeneic Hematopoietic Cell Transplant
15
Pipeline Programs↗
5
Active Trials↗
8
Companies Involved↗
Allogeneic Hematopoietic Cell Transplant is an emerging landscape with 15 programs across 8 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 215
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
12 of 14 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.
Analysis
Trial Status
26
clinical trials
Completed10 · 38%
Terminated9 · 35%
Recruiting4 · 15%
Unknown status1 · 4%
Withdrawn1 · 4%
Active, not recruiting1 · 4%
Clinical Trials
Trial Activity
26 trials
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Recruiting·—·Phase 2·NCT05501756·60 enrolled
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02342613·32 enrolled
Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Completed·—·Phase 2·NCT01665677·69 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)